

Cite this: *RSC Adv.*, 2019, 9, 38897

Metal-free synthesis of 1,*N*⁶-ethenoadenines from *N*⁶-propargyl-adenines *via* NIS mediated radical cascade reaction†

Ruchun Yang,^{ab} Si Deng,^b Xiang-you Dong,^b Xianrong Song,^b Hu Cai,^{b*} Jiang Bai^b and Qiang Xiao^{b*}

In the present paper, an efficient approach for the construction of 1,*N*⁶-ethenoadenines from conveniently prepared *N*⁶-propargyl-adenines is developed. This reaction merges *N*-iodosuccinimide radical initiation and aerobic aminooxygenation in dioxane. This mild, 5-*exo-dig*, and metal-free cascade reaction could be applied to a wide substrate scope to provide 1,*N*⁶-ethenoadenines in moderate to good yields. The reaction mechanism was proposed and tested using radical inhibitor (butylated hydroxytoluene) and isotopic labelling (¹⁸O₂) experiments.

Received 26th September 2019

Accepted 18th November 2019

DOI: 10.1039/c9ra09198j

rsc.li/rsc-advances

Introduction

The development of efficient strategies for the synthesis of nitrogen containing heterocycles has attracted tremendous interest from both academic and pharmaceutical companies. In the past decades, various approaches have been developed and great progress has been achieved.¹ Among these approaches, the cascade reaction turned out to be the most extensively employed one due to its high efficiency and step economy, without the isolation of possible miscellaneous intermediates.² However, the corresponding nitrogen or sulphur atoms in the heterocyclic substrates generally possess strong coordinating ability to metal ions, which could lead to catalyst poisoning and side reactions.³ Thus, it is highly desirable to develop a new metal-free cascade reaction particularly for multiple nitrogen-containing heterocycles, such as nucleosides.

In our continuous effort to develop fluorogenic nucleosides for nucleic acid analysis,⁴ 1,*N*⁶-ethenoadenosines have attracted our attention because of their unique biological activities and conjugated structural skeleton (Fig. 1).⁵ Specifically, 1,*N*⁶-ethenoadenine 1 showed strongly fluorescent emission depending on the surrounding environment, which has been extensively used in analyzing the structure and functions of nucleic acids.⁶ Furthermore, it has been also recognized as a biomarker for the study of oxidative stress-related diseases and genetic damages

associated with cancer.⁷ In addition, 9-hydroxy-1,*N*⁶-benzetheno-2'-deoxyadenosine 2 was firstly identified as DNA adduct with *p*-benzoquinone formed by peroxidase activation of benzene metabolites, which is well-known to cause acute leukemia in humans and bone marrow toxicity.⁸ Ethenoadenine 3 is another adducts of adenosine with 4-oxo-2-nonenal, which is a novel product of lipid peroxidation and may play an important role in lipid hydroperoxide-mediated carcinogenesis.⁹

Despite of the significance of 1,*N*⁶-ethenoadenosines mentioned above, literatures survey revealed that the availability of their synthetic approaches was very rare. The typical synthetic route is the reaction of α -halocarbonyl compounds with purine.¹⁰ Therefore, the development of novel methodology with high efficiency and structural diversity is in high demand.

In recent years, propargylamine derivatives, bearing electrophilic triple bonds, have emerged as promising cascade synthons for heterocycle synthesis.¹¹ For example, imidazo[1,2-*a*]pyridines were readily prepared from 3-




Fig. 1 Representative examples of 1,*N*⁶-ethenoadenosines.

^aInstitute of Chemistry, Nanchang University, Nanchang 330031, Jiangxi Province, China. E-mail: caihu@ncu.edu.cn

^bInstitute of Organic Chemistry, Jiangxi Science & Technology Normal University, Key Laboratory of Organic Chemistry, Nanchang 330013, Jiangxi Province, China. E-mail: xiaoqiang@tsinghua.org.cn

† Electronic supplementary information (ESI) available. CCDC 1955922. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c9ra09198j



phenylpropiolaldehyde and 2-aminopyridine by using either copper(i) or gold(i) catalyst along with air as the oxidant (Scheme 1a, (1) and (2)).¹² Later on, Das *et al.* further developed an improved and general metal-free aminoxygenation of alkynes for the rapid construction of 3-arylimidazo[1,2-*a*]pyridines (Scheme 1a, (3)).¹³ According to the proposed mechanism, NIS works as an iodine cation donor, which may coordinate with the alkyne to form iodonium intermediate. Then nucleophilic addition of water followed by elimination of hydrogen iodide afforded the target product. Very recently, Huang *et al.* reported a metal free synthesis of aroylimidazo[1,2-*a*]pyridine *via* intramolecular dehydrogenative aminoxygenation of alkynes, which use I₂ as catalyst and TBHP as an oxidant (Scheme 1b).¹⁴ But this approach has never been applied to purine substrates. In 2014, Guo *et al.* developed a novel approach to construct purine-fused 1,*N*⁶-ethenoadenine *via* copper-catalysed intramolecular cyclization of *N*⁶-propargyl-adenine at high temperature. However, this approach always affords two regioisomers (Scheme 1c).¹⁵


Based on examples mentioned previously in the literature, we envisioned that *N*⁶-propargyl-adenine could be activated by NIS to form iodonium intermediate. The subsequent *N*-1 mediated nucleophilic attacking to the resulting iodonium

intermediate would generate 1,*N*⁶-ethenoadenines products directly. If it works, this new metal free synthetic route could provide direct access to 1,*N*⁶-ethenoadenines in one step cascade reaction from readily available starting material.

Results and discussion

To test our hypothesis, we initially mixed readily prepared *N*⁶-propargyl-adenine **1a** with 1 eq. NIS in DCM at room temperature (Table 1, entry 1). It is encouraging to find that a fluorescent product was obtained in moderate yield of 46%. From NMR spectra, there is only one CH₂ group present which belong to *N*³-benzyl group and there is a new carbonyl and a new aromatic CH appeared. In addition, element analysis excluded iodine atom in the target molecule. After extensive characterization analysis, the target structure was determined to be the oxidized cascade cyclization product **2a**.

In order to improve the efficiency, a series of solvents with different polarity, such as DMF, dioxane, CH₃CN, CH₃OH, and DMSO, were screened (entries 1–7). Dioxane proved to be optimal and gave the best yield of 74% (entry 4). Moreover, 1.2 eq. NIS is sufficient to complete this transformation (entry 10). Increasing the reaction temperature led to slightly lower yields (entries 12–13). Furthermore, the effect of different halo sources (NCS, NBS and iodine) were examined (entries 14–16). Neither NBS nor NCS could promote the cascade reaction and only trace



Scheme 1 Diverse constructions of imidazo[1,2-*a*]pyridine.

Table 1 Optimization of reaction conditions^a

Entry	Halo source	Solvent	Time	Yield ^b
1	NIS	DCM	12 h	46
2	NIS	CH ₃ OH	12 h	34
3	NIS	DMSO	12 h	36
4	NIS	Dioxane	12 h	74
5	NIS	DMF	12 h	23
6	NIS	CH ₃ CN	12 h	52
7	NIS	THF	12 h	48
8	—	Dioxane	12 h	None
9	NIS (0.5 eq.)	Dioxane	12 h	33
10	NIS (1.2 eq.)	Dioxane	12 h	75
11	NIS (1.5 eq.)	Dioxane	12 h	73
12 ^c	NIS (1.2 eq.)	Dioxane	12 h	65
13 ^d	NIS (1.2 eq.)	Dioxane	12 h	63
14	NBS	Dioxane	12 h	Trace
15	NCS	Dioxane	12 h	None
16	I ₂	Dioxane	12 h	13
17 ^e	NIS (1.2 eq.)	Dioxane	12 h	46
18 ^f	NIS (1.2 eq.)	Dioxane	12 h	Trace

^a Reaction conditions: 0.1 mmol **1a**, 1.0 eq. NIS, in 2.0 mL dioxane under air, room temperature. ^b Isolated yields. ^c Reaction performed at 50 °C. ^d Reaction performed at 80 °C. ^e Dark, 1 atm O₂. ^f Sunlight, argon atmosphere.

amount of desired product could be detected. Using iodine only provided 13% yield. In addition, the reaction performed under argon gave only trace amount of product, revealing the essential role of oxygen. Furthermore, the reaction became sluggish in absence of light. Thus, we chose dioxane as solvent, 1.2 eq. NIS, room temperature, and opening to air as the reaction conditions for further investigation (Table 2).

To demonstrate the generality of this transformation, various substituted N^6 -propargyl-adenines were subjected to the optimized conditions. Firstly, the effect of aromatic ring bearing different R substituents attached to alkyne was evaluated. A series of halogens including F, Cl and Br were compatible with this cascade reaction and the desired products were generated in good yields (**2b–2d**). It was found that substrates bearing electron-withdrawing substituents (CN, NO₂, CF₃ *etc.*) afforded product in higher yield than the substrate bearing electron-donating substituents (Me, OMe, phenyl *etc.*). However, the strong electron-donating group substituted at the *para* position of the alkyne remarkably retarded the reaction (**2m**, trace). The electron-donating group at the *meta* position also significantly reduced the reaction yield (**2n**, 56%). Steric hindered substrates proved to be not suitable for the reaction and only low yields were obtained (**2k**, **2o** and **2q**). Furthermore, the effect of the substituent attached on purine, including N^7 -benzyl and N^9 -Ts

substituted substrates also gave the corresponding 1, N^6 -ethenoadenines in good yields (**2r**, 65%; **2s**, 83%). Fortunately, a single crystal suitable for X-ray crystallography of **2n** was obtained and its structure was unambiguously confirmed in Fig. 2, which further verified the proposed structure.


Next, substrate scope was extended to ribose nucleoside substrates **1t–1w** under the optimized reaction condition (Table 3). The corresponding 1, N^6 -ethenoadenosines were also obtained in good yields (**2t–2w**). Their UV and fluorescent spectroscopies were recorded. From UV spectrum, they showed a unique adsorption at 340 nm (see ESI†). Furthermore, fluorescence spectrum of **2w** showed emission wave at 437 nm and excitation at 270 nm, which is very useful for nucleic acid research when incorporated into oligonucleotides. The related work is on-going and will be reported in due course.

To gain insights into the reaction mechanism, we revisited the optimization process. We observed three clear facts: (1) the oxygen is essential for this transformation. (2) Other NXS except for NIS cannot afford the desired products in good yield. (3) Retarded reaction was observed under dark environment. Considering NIS could generate iodine radical, we assumed that the reaction might be a radical mechanism, which is contrary to our initially proposed mechanism through iodonium intermediate.

In order to test our hypothesis, control experiments were performed as shown in Scheme 2. When the radical inhibitor butylated hydroxytoluene (BHT) was added to the reaction, we observed that the reaction was almost inhibited, which indicated that a radical intermediate maybe involved in this cascade reaction (Scheme 2a). In order to further verify the resource of oxygen atom in oxidation products, isotopic labelling experiment using ¹⁸O₂ were conducted. The labeled product **2f-O**¹⁸ can be confirmed by HRMS analysis (Scheme 2b). The result demonstrated that the oxygen atom of oxidation product **2a** was utmost originated from O₂. To the best of our knowledge, bifunctionalization of alkyne by radical reaction and aerobic aminoxygenation is rarely reported.¹⁶ In addition, the cyclization reaction cannot happen if the *NH*-6 was blocked by methyl group.

Based on these preliminary mechanistic studies and previous reports, a plausible mechanism for this cascade reaction is proposed as shown in Scheme 3. Initially, the reaction of the N^6 -H of starting material **1** with NIS gave intermediate **A**,

Table 2 Metal-free cascade cyclization–oxidation of N^6 -propargyl-adenine^a



^a Reaction conditions: 0.1 mmol **1a–1s**, 1.2 eq. NIS, in 2.0 mL dioxane under air; isolated yields.






Fig. 2 ORTEP diagram for compound **2n**. Thermal ellipsoids are drawn at the 30% probability level.


Table 3 Metal-free cascade cyclization–oxidation of N^6 -propargyl-adenosines^a



^a Reaction conditions: 0.1 mmol **1t–1w**, 1.2 eq. NIS, in 2.0 mL dioxane under air; isolated yields.



Scheme 2 Mechanistic studies and control experiments.



Scheme 3 Proposed reaction mechanism.

which is easily hemolytic to form radical intermediate **B**. The tautomerism of radical intermediate **B** could deliver $N-1$ radical intermediate **C**. Then, the $N-1$ radical attack the triple bond through *5-exo-dig* configuration to afford cyclized radical intermediate **D** in higher yields. After oxidation of **D** using molecular O_2 , the resulted intermediate **E** rearranged to give ethenoadenine **2** after elimination of HOI.

Conclusions

In summary, an efficient approach for the preparation of $1,N^6$ -ethenoadenine from N^6 -propargyl-adenine was developed. This approach features: (1) easily prepared starting material; (2) NIS mediated radical and metal-free cascade reaction; (3) air used as an oxygen source and as the oxidant. We believe that this methodology provides a complementary synthetic approach to $1,N^6$ -ethenoadenine architectures and the NIS mediated radical cascade reaction of N -propargylamine under air opens up new opportunities for the synthesis of other heterocycles.

Experimental

General procedure for the preparation of products

NIS (27.0 mg, 0.12 mmol) was added to a stirred solution of **1a–1w** (0.1 mmol) in dioxane (2 mL) under open air atmosphere. The resulting mixture was stirred at room temperature and the progress of the reaction was monitored by thin-layer chromatography. After completion of the reaction, the mixture was quenched by slow addition of saturated sodium thiosulfate and extracted with EtOAc (3×5 mL). The combined organic layer was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel to give the corresponding product **2a–2w**.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The financial support from the National Natural Science Foundation of China (No. 21676131, No. 21571094, and No. 21861026) and the Bureau of Science & Technology of Jiangxi Province (No. 20143ACB20012) are gratefully acknowledged.

Notes and references

- For selected reviews on synthetic progress and pharmaceutical application of heterocycles, see: (a) D. C. Blakemore, L. Castro, I. Churcher, D. C. Rees, A. W. Thomas, D. M. Wilson and A. Wood, *Nat. Chem.*, 2018, **10**, 383; (b) J. Akhtar, A. A. Khan, Z. Ali, R. Haider and M. S. Yar, *Eur. J. Med. Chem.*, 2017, **125**, 143; (c) A. P. Taylor, R. P. Robinson, Y. M. Fobian, D. C. Blakemore, L. H. Jones and O. Fadeyi, *Org. Biomol.*

- Chem.*, 2016, **14**, 6611; (d) E. Vitaku, D. T. Smith and J. T. Njardarson, *J. Med. Chem.*, 2014, **57**, 10257.
- 2 For selected reviews on cascade synthesis of heterocycles, see: (a) J. Lei, J.-P. Meng, D.-Y. Tang, B. Frett, Z.-Z. Chen and Z.-G. Xu, *Mol. Diversity*, 2018, **22**, 503; (b) J. Xuan and A. Studer, *Chem. Soc. Rev.*, 2017, **46**, 4329; (c) B. Zhang and A. Studer, *Chem. Soc. Rev.*, 2015, **44**, 3505; (d) C. J. Ball and M. C. Willis, *Eur. J. Org. Chem.*, 2013, 425.
- 3 For selected examples about discussing potential poisoning catalysis by heterocycles, see: (a) S. J. Tereniak and S. S. Stahl, *J. Am. Chem. Soc.*, 2017, **139**, 14533; (b) R. P. Downs, A. L. Chin, K. M. Dean and J. D. Carrick, *J. Heterocycl. Chem.*, 2017, **54**, 3008; (c) C. Shen, A. Spannenberg and X.-F. Wu, *Angew. Chem., Int. Ed.*, 2016, **55**, 5067; (d) Y.-J. Liu, H. Xu, W.-J. Kong, M. Shang, H.-X. Dai and J.-Q. Yu, *Nature*, 2014, **515**, 389.
- 4 (a) C. Hu, Z. Ruan, H. Ding, Y. Zhou and Q. Xiao, *Molecules*, 2017, **22**, 643; (b) H.-X. Ding, M. Wan, R.-C. Yang, W.-H. Xiao and Q. Xiao, *Chin. J. Org. Chem.*, 2008, **28**, 330; (c) Q. Xiao, R. T. Ranasinghe, A. M. P. Tang and T. Brown, *Tetrahedron*, 2007, **63**, 3483.
- 5 (a) Z. Jahnz-Wechmann, G. R. Framski, P. A. Januszczczyk and J. Boryski, *Front. Chem.*, 2016, **4**, 19; (b) C.-H. Wu, J. Zhou and C.-B. Chen, *Chin. J. Org. Chem.*, 2006, **26**, 1457.
- 6 (a) P. Virta, T. Holmstrom, T. Munter, T. Nyholm, L. Kronberg and R. Sjöholm, *Nucleosides, Nucleotides Nucleic Acids*, 2003, **22**, 85; (b) J. Wierzchowski, A. Stachelska-Wierzchowska, B. Wielgus-Kutrowska and A. Bzowska, *Curr. Pharm. Des.*, 2017, **23**, 6948.
- 7 M. T. Leithauser, A. Liem, B. C. Stewart, E. C. Miller and J. A. Miller, *Carcinogenesis*, 1990, **11**, 463.
- 8 A. Chenna, B. Hang, B. Rydberg, E. Kim, K. Pongracz, W. J. Bodell and B. Singer, *Proc. Natl. Acad. Sci. U. S. A.*, 1995, **92**, 5890.
- 9 (a) A. Winczura, A. Czuby, K. Winczura, K. Maslowska, M. Nalecz, D. A. Dudzinska, M. Saparbaev, K. Staron and B. Tudek, *DNA Repair*, 2014, **22**, 1; (b) H. Bartsch and J. Nair, *Toxicology*, 2000, **153**, 105.
- 10 S. Mikkola, N. Koissi, K. Ketomaki, S. Rauvala, K. Neuvonen and H. Lonnberg, *Eur. J. Org. Chem.*, 2000, 2315.
- 11 (a) K. Lauder, A. Toscani, N. Scalacci and D. Castagnolo, *Chem. Rev.*, 2017, **117**, 14091; (b) V. A. Peshkov, O. P. Pereshivko, A. A. Nechaev, A. A. Peshkov and E. V. Van der Eycken, *Chem. Soc. Rev.*, 2018, **47**, 3861; (c) J. Xie, Z. Guo, Y. Huang, Y. Qu, H. Song, H. Song, Y. Liu and Q. Wang, *Adv. Synth. Catal.*, 2019, **361**, 490; (d) E. Vessally, S. Soleimani-Amiri, A. Hosseinian, L. Edjlali and A. Bekhradnia, *RSC Adv.*, 2017, **7**, 7079.
- 12 (a) H. Cao, X. Liu, J. Liao, J. Huang, H. Qiu, Q. Chen and Y. Chen, *J. Org. Chem.*, 2014, **79**, 11209; (b) H. Zhan, L. Zhao, J. Liao, N. Li, Q. Chen, S. Qiu and H. Cao, *Adv. Synth. Catal.*, 2015, **357**, 46.
- 13 K. R. Reddy, A. P. Gupta and P. Das, *Asian J. Org. Chem.*, 2016, **5**, 900.
- 14 Y. He, W. Yin, J. Wang, J. Huang, X. Pang, C. Gan, F. Yang and C. Huang, *Org. Chem. Front.*, 2018, **5**, 1772.
- 15 R. L. Li, L. Liang, M. S. Xie, G. R. Qu, H. Y. Niu and H. M. Guo, *J. Org. Chem.*, 2014, **79**, 3665.
- 16 For recent examples, see: (a) J. Santhi and B. Baire, *Adv. Synth. Catal.*, 2016, **358**, 3817; (b) W. Chen, Y. Zhang, P. Li and L. Wang, *Org. Chem. Front.*, 2018, **5**, 855.